AptarGroup, Inc. 2001 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2001. AptarGroup, Inc. is a leading global supplier of innovative dispensing systems, including pumps, dispensing closures, and aerosol valves. The company serves five principal markets: fragrance/cosmetic, personal care, pharmaceutical, household, and food/beverage. Operations are organized into two reportable segments: Dispensing Systems (aggregating four business units) and SeaquistPerfect (a separate segment due to lower historical economic performance). The company operates manufacturing facilities in North America, Europe, Asia, and South America, employing approximately 6,600 full-time employees.
Key Financial Metrics
The filing text incorporates detailed financial statements by reference and does not explicitly state total revenue, net income, or cash flow figures in the narrative sections provided. However, the following specific metrics and data points are disclosed:
- Research and Development (R&D): Expenditures were $25.9 million in 2001 (compared to $26.9 million in 2000 and $25.6 million in 1999).
- Export Sales (U.S.): $62.2 million in 2001.
- Argentina Subsidiary Sales: Approximately $8 million in 2001.
- Foreign Exchange Impact: An unrealized foreign exchange loss of approximately $140,000 was reported due to the devaluation of the Argentine Peso.
- Valuation Reserves (in thousands):
- Allowance for doubtful accounts: Ended 2001 at $7,366.
- Inventory obsolescence reserve: Ended 2001 at $10,594.
- Stock Information: As of March 14, 2002, there were 35,880,331 shares of Common Stock outstanding. The aggregate market value held by non-affiliates was approximately $1.15 billion.
Note: Specific values for total revenue, profit margins, debt levels, and liquidity ratios are not present in the provided text as they are incorporated by reference from the Annual Report to Stockholders.
Material Changes and Operational Highlights
- Strategic Initiative: In April 2001, the company launched a project to improve efficiency in mass-market pump production. This involves closing a U.S. molding operation and consolidating operations in Italy.
- Expected total charges: Approximately $10 million before taxes.
- Cash outlays: Approximately $3 million.
- Non-cash charges (impairments, depreciation): Approximately $7 million.
- SeaquistPerfect Segment: The company implemented cost reductions and price increases in 2001 for North American aerosol valve customers. Profitability is expected to continue increasing as the segment selectively exits non-strategic standard aerosol valve business in 2002.
- Product Mix (2001 Net Sales):
- Pumps: 62%
- Closures: 22%
- Aerosol Valves: 14%
- Market Mix (2001 Net Sales): Fragrance/Cosmetic (32%), Personal Care (31%), Pharmaceutical (22%), Household (9%), Food/Beverage (6%).
- Geographic Sales: Europe accounted for approximately 54% of net sales in 2001.
Outlook, Risks, and Management Commentary
Outlook and Strategy: Management expects the mix of sales by product and market to remain approximately the same in 2002. Growth strategies include geographic expansion (Latin America, Eastern Europe, Asia), converting non-dispensing applications to dispensing systems, and developing new technologies (e.g., electronic dispensing systems, "Clic and Dream" fragrance samples).
Risks and Contingencies:
- Foreign Currency: Significant exposure to the Euro, British pound, and South American/Asian currencies. A strengthening U.S. dollar has a dilutive translation effect.
- Argentina Economic Crisis: Business in Argentina is expected to be disrupted, though the impact on worldwide results is not expected to be significant.
- Customer Concentration: While no single customer accounts for more than 5% of sales, the customer base is consolidating, which may lead to pricing pressures.
- Regulatory Environment: Regulations regarding Volatile Organic Compounds (VOCs) and aerosol propellants (CFC phase-out) impact demand. Medical cost containment policies could affect pharmaceutical sales.
- Supply Chain: Dependence on specific suppliers for unique technical components (aerosol valves, pumps) and approved plastic resins for pharmaceutical products.
Investor Verification Checklist
- Verify the full consolidated financial statements (Revenue, Net Income, Cash Flow) in the 2001 Annual Report to Stockholders (pages 52-81), as these figures are incorporated by reference and not explicitly listed in this text.
- Review the Strategic Initiative charges in Note 12 of the financial statements to confirm the exact timing and impact of the $10 million expense.
- Assess the impact of the Argentine Peso devaluation on future operations beyond the reported $140,000 unrealized loss.
- Monitor the progress of the SeaquistPerfect segment's exit strategy for non-strategic standard aerosol valve business in 2002.
- Check the Quarterly Data (Unaudited) in Note 18 of the Annual Report for stock price performance and quarterly earnings trends.